Skip to main content
Publications
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554
Vickers A, Nag A, Devine B, Sands BE, Panaccione R, Peyrin-Biroulet L, Danese S, Vermeire S, Gorelick KJ, Goetsch M, Hartley L. Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. Poster presented at the 2020 15th Congress of the European Crohn’s and Colitis Organisation (ECCO); February 2020. Vienna, Austria.
Vickers A, Nag A, Devine B, Sands BE, Panaccione R, Peyrin-Biroulet L, Danese S, Vermeire S, Gorelick KJ, Goetsch M, Hartley L. Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. Poster presented at the 2020 European Crohn's and Colitis Organisation Annual Congress; February 2020. Vienna, Austria.
Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, Clar C, Germano R, Lunn HR, Frost G, Rees K. Whole grain cereals for the primary or secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD005051. doi: 10.1002/14651858.CD005051.pub3